March 10th 2020
Paris, March 10, 2020 – 5.45 pm CET
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces that it has reached a major milestone by achieving record individual support of 2 years with its bioprosthesis within the framework of the PIVOTAL study.
Stéphane Piat, Chief Executive Officer of CARMAT, comments: “This is major news today for CARMAT. Indeed, within the context of the clinical development, we assess both the efficacy and the safety of our bioprosthesis, of which the durability is a decisive factor for patients. Passing two-year period of individual functioning is very encouraging, and confirms the capacity of our device to provide long-term support, which is one of our two key objectives along with that of being a bridge to a heart transplant.”